DPLG3

small molecule inhibitor; a N, C-capped dipeptide that reversibly inhibits immunoproteasome

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Colitis 01/01/2020 - "Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation." 01/01/2020 - "In this study, we evaluated the therapeutic effects of a specific small molecule inhibitor of the chymotryptic-like β5i subunits of the immunoproteasome, DPLG3, in a preclinical murine colitis model and explored the underlying molecular mechanism for the immune suppression. " 01/01/2020 - "DPLG3 showed significant effects in attenuating the disease progression in experimental colitis, reducing the body and spleen weight losses, and colon length shortening compared to vehicle-treated controls and to the well studied immunoproteasome inhibitor ONX-0914. "
2.	Disease Progression 01/01/2020 - "DPLG3 showed significant effects in attenuating the disease progression in experimental colitis, reducing the body and spleen weight losses, and colon length shortening compared to vehicle-treated controls and to the well studied immunoproteasome inhibitor ONX-0914. "
3.	Weight Loss (Weight Reduction) 01/01/2020 - "DPLG3 showed significant effects in attenuating the disease progression in experimental colitis, reducing the body and spleen weight losses, and colon length shortening compared to vehicle-treated controls and to the well studied immunoproteasome inhibitor ONX-0914. "

1.	Therapeutic Uses